WO2012136813A9 - Agents pour un diagnostic par radar médical - Google Patents

Agents pour un diagnostic par radar médical Download PDF

Info

Publication number
WO2012136813A9
WO2012136813A9 PCT/EP2012/056363 EP2012056363W WO2012136813A9 WO 2012136813 A9 WO2012136813 A9 WO 2012136813A9 EP 2012056363 W EP2012056363 W EP 2012056363W WO 2012136813 A9 WO2012136813 A9 WO 2012136813A9
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
agents
radar
medical radar
medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/056363
Other languages
English (en)
Other versions
WO2012136813A2 (fr
WO2012136813A3 (fr
Inventor
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitetet i Oslo
Original Assignee
Universitetet i Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet i Oslo filed Critical Universitetet i Oslo
Publication of WO2012136813A2 publication Critical patent/WO2012136813A2/fr
Publication of WO2012136813A3 publication Critical patent/WO2012136813A3/fr
Publication of WO2012136813A9 publication Critical patent/WO2012136813A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/0507—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0404—X-ray contrast preparations containing barium sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La présente invention porte sur l'utilisation d'agents de contraste en imagerie à base de radar, en particulier en imagerie médicale. L'invention porte également sur l'utilisation d'agents de contraste dans le diagnostic de différentes maladies utilisant une technologie à base de radar. L'invention porte également sur un appareil pour imagerie à base de radar comprenant un agent de contraste.
PCT/EP2012/056363 2011-04-07 2012-04-05 Agents pour un diagnostic par radar médical Ceased WO2012136813A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20110544 2011-04-07
NO20110544 2011-04-07

Publications (3)

Publication Number Publication Date
WO2012136813A2 WO2012136813A2 (fr) 2012-10-11
WO2012136813A3 WO2012136813A3 (fr) 2013-01-17
WO2012136813A9 true WO2012136813A9 (fr) 2013-03-14

Family

ID=45998277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/056363 Ceased WO2012136813A2 (fr) 2011-04-07 2012-04-05 Agents pour un diagnostic par radar médical

Country Status (1)

Country Link
WO (1) WO2012136813A2 (fr)

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032567A (en) 1972-02-16 1977-06-28 Schering Aktiengesellschaft Triiodoisophthalic acid monoamino acid amides, process for the preparation thereof, and use thereof as x-ray contrast media
US3908657A (en) 1973-01-15 1975-09-30 Univ Johns Hopkins System for continuous withdrawal of blood
DE2628517C2 (de) 1976-06-23 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen Dicarbonsäure-bis(3,5-dicarbamoyl-2,4,6-trijodanilid)-Verbindungen, Verfahren zu ihrer Herstellung und Röntgenkontrastmittel
US4125599A (en) 1976-08-19 1978-11-14 Mallinckrodt, Inc. X-ray contrast agents
CH626873A5 (fr) 1977-03-28 1981-12-15 Bracco Ind Chimica Spa
NL7905354A (nl) 1978-07-14 1980-01-16 Schering Ag Als roentgen-contrastmiddelen bruikbare trijoodbenzonitril-derivaten.
DE2852094A1 (de) 1978-11-30 1980-06-12 Schering Ag Neue roentgenkontrastmittel
DE2909439A1 (de) 1979-03-08 1980-09-18 Schering Ag Neue nichtionische roentgenkontrastmittel
IT1193211B (it) 1979-08-09 1988-06-15 Bracco Ind Chimica Spa Derivati dell'acido 2,4,6-triiodo-isoftalico,metodo per la loro preparazione e mezzi di contrasto che li contengono
IT1207226B (it) 1979-08-09 1989-05-17 Bracco Ind Chimica Spa Derivati dell'acido 2,4,6-triiodo-isoftalico, metodo per la loro preparazione e mezzi di contrasto che li contengono.
DE3038853A1 (de) 1980-10-10 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue n-hydroxy-alkylierte dicarbonsaeure-bis-(3,5-dicarbamoyl-2,4,6-trijodanilide), deren herstellung und diese enthaltende roentgenkonstrastmittel (ii)
DE3044814A1 (de) 1980-11-25 1982-07-08 Schering Ag, 1000 Berlin Und 4619 Bergkamen Unsymmetrisch substituierte dicarbonsaeure-bis-(2,4,6-trijod-anilide), deren herstellung und diese enthaltende roentgenkontrastmittel
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
DE3150916A1 (de) 1981-12-18 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-hydroxyaethylierte 2,4,6-trijodaminoisiophthalsaeure-bis- trihydroxybutylamide, deren herstellung und diese enthaltende roentgenkontrastmittel"
US4396598A (en) 1982-01-11 1983-08-02 Mallinckrodt, Inc. Triiodoisophthalamide X-ray contrast agent
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5204086A (en) 1982-10-01 1993-04-20 Nycomed Imaging As X-ray contrast agent
ATE20733T1 (de) 1982-11-08 1986-08-15 Nyegaard & Co As Roentgenkontrastmittel.
US5141738A (en) 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
DE3324235A1 (de) 1983-07-01 1985-01-10 Schering AG, 1000 Berlin und 4709 Bergkamen Neue komplexbildner, komplexe und komplexsalze
US5618514A (en) 1983-12-21 1997-04-08 Nycomed Imaging As Diagnostic and contrast agent
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5160726A (en) 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
US5132409A (en) 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
DE3731542A1 (de) 1987-09-17 1989-03-30 Schering Ag Neue dicarbonsaeure-bis(3,5-dicarbamoyl-2,4,6-triiod-anilide), verfahren zu deren herstellung sowie diese enthaltende roentgenkontrastmittel
DE3739098A1 (de) 1987-11-16 1989-05-24 Schering Ag Neue substituierte dicarbonsaeure-bis(3,5-dicarbamoyl-2,4,6- trijod-anilide), verfahren zu deren herstellung sowie diese enthaltende roentgenkontrastmittel
US5425366A (en) 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
KR0133132B1 (ko) 1988-02-05 1998-04-17 쉐링 아게, 베를린 운트 베르크카멘 초음파 조영제, 이의 제법 및 이의 진단제로서의 용도
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5030956A (en) 1989-04-25 1991-07-09 Murphy Quentin M Radar tomography
JP2726520B2 (ja) 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
US5232685A (en) 1989-11-03 1993-08-03 Schering Aktiengesellschaft Nonionic x-ray contrast medium with high iodine content
DE3937118A1 (de) 1989-11-03 1991-05-08 Schering Ag Nichtionische roentgenkontrastmittel mit hohem jodgehalt
US5614638A (en) 1989-11-29 1997-03-25 Bracco International B.V. Nonionic radiographic contrast agents
US5191120A (en) 1989-12-13 1993-03-02 Mallinckrodt Medical, Inc. Process for preparing nonionic X-ray contrast agents
US5075502A (en) 1989-12-13 1991-12-24 Mallinckrodt, Inc. Nonionic x-ray contrast agents, compositions and methods
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (fr) 1990-04-02 1993-05-01 Sint Sa
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
DE4035760A1 (de) 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5019371A (en) 1990-11-21 1991-05-28 Mallinckrodt Medical, Inc. Novel x-ray contrast agents, compositions and methods
US5356613A (en) 1991-03-18 1994-10-18 Mallinckrodt Medical, Inc. X-ray contrast agents, compositions and methods
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
FI935394L (fi) 1991-06-03 1993-12-02 Nycomed Imaging As Foerbaettringar i betraeffande kontrastmedel
ATE126066T1 (de) 1991-07-22 1995-08-15 Bracco Int Bv Anwendung von chelaten von konjugaten mit paramagnetischen metallen für targetting.
US5409688A (en) 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
US5648062A (en) 1992-01-09 1997-07-15 Nycomed Imaging As Contrast agents consisting of galactose particles
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
US5464696A (en) 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
EP0679066A4 (fr) 1992-11-02 1996-04-03 Univ Drexel Melanges de microbulles stabilisees par un tensio-actif, et leurs procedes de preparation et d'utilisation.
IL110391A (en) 1993-07-30 1998-12-06 Zambon Spa Process for the crystallization of iopamidol
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
US6217849B1 (en) 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
ATE234638T1 (de) 1993-12-15 2003-04-15 Bracco Research Sa Gas-mischungen verwendbar als ultraschallkontrastmittel
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
NO940711D0 (no) 1994-03-01 1994-03-01 Nycomed Imaging As Preparation of gas-filled microcapsules and contrasts agents for diagnostic imaging
ZA952485B (en) 1994-03-28 1995-12-15 Nycomed Imaging As Liposomes
GB9419206D0 (en) 1994-09-23 1994-11-09 Nycomed Innovation Ab Contrast media
GB9419203D0 (en) 1994-09-23 1994-11-09 Nycomed Innovation Ab Contrast media
US6310243B1 (en) 1994-09-23 2001-10-30 Nycomed Imaging As Iodinated x-ray contrast media
US5702722A (en) 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
IT1271107B (it) 1994-11-29 1997-05-26 Zambon Spa Processo per la preparazione di un intermedio utile nella sintesi di composti organici
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
WO2004073750A1 (fr) 1995-06-07 2004-09-02 Harald Dugstad Ameliorations relatives a des agents de contraste
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
HU220965B1 (hu) 1995-09-08 2002-07-29 Bracco International B.V. Eljárás (S)-N,N'-bisz[2-hidroxi-1-(hidroxi-metil)-etil]-5-[(2-hidroxi-1-oxo-propil)-amino]-2,4,6-trijód-1,3-benzol-dikarboxamid vízből való kristályosítására
GB9600427D0 (en) 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
JP4418033B2 (ja) 1996-02-19 2010-02-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤のまたはそれに関する改良
MXPA99001053A (es) 1996-08-02 2002-03-11 Nycomed Imaging As Mejoramientos en o que se relacionan con agentes de contraste.
EP0928809B1 (fr) 1996-08-30 2003-10-22 Meito Sangyo Kabushiki Kaisha Composite contenant un derive de polysaccharide et un oxyde metallique magnetique
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
EP0971747B1 (fr) 1996-10-28 2005-12-28 Amersham Health AS Agents de contraste
WO1998018497A2 (fr) 1996-10-28 1998-05-07 Nycomed Imaging As Agents de contraste
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
BR9712683A (pt) 1996-10-28 1999-10-19 Nyomed Imaging A S Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente.
US6054118A (en) 1997-01-22 2000-04-25 Nycomed Imaging As Contrast agents comprising two types of gas-containing microparticles
GB9708240D0 (en) 1997-04-23 1997-06-11 Nycomed Imaging As Improvements in or relating to contrast agents
GB9712524D0 (en) * 1997-06-16 1997-08-20 Nycomed Imaging As Method
US6045777A (en) 1997-06-30 2000-04-04 Acusphere, Inc. Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
IT1302200B1 (it) 1998-09-11 2000-07-31 Dibra Spa PROCESSO PER LA PREPARAZIONE DELLA S-N,N'-BIS°2-IDROSSI-1-(IDROSSIMETIL)ETILé-5-°(2-IDROSSI-1-
EP1140211A1 (fr) 1998-10-12 2001-10-10 Mallinckrodt Inc. Agents de contraste pour ultrasons
IT1303797B1 (it) 1998-11-27 2001-02-23 Bracco Spa Processo per la preparazione di n,n'-bis(2,3-diidrossipropil)-5-((idrossiacetil)metilammino)-2,4,6-triiodo-1,3-benzendicarbossammide.
US7807137B1 (en) 1998-12-22 2010-10-05 University Of Puerto Rico Iron-based contrast agent
US6803485B2 (en) 1999-02-26 2004-10-12 Bracco Imaging S.P.A. Process for the preparation of iopamidol
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US6406680B1 (en) 1999-09-17 2002-06-18 Nycomed Imaging As X-ray contrast agents
US7745590B1 (en) 2001-11-13 2010-06-29 University Of Utah Research Foundation Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof
US7010339B2 (en) 2002-07-29 2006-03-07 The United States Of America As Represented By The Secretary Of The Navy Hybrid lidar-radar for medical diagnostics
US7368099B2 (en) 2003-02-27 2008-05-06 Kyushu University, National University Corporation MRI contrast agents
US20040249257A1 (en) 2003-06-04 2004-12-09 Tupin Joe Paul Article of manufacture for extracting physiological data using ultra-wideband radar and improved signal processing techniques
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7588751B2 (en) 2004-07-21 2009-09-15 Konica Minolta Medical & Graphic, Inc. Liposome-containing radiographic contrast medium and preparation method thereof
EP1762563A1 (fr) 2005-09-13 2007-03-14 BRACCO IMAGING S.p.A. Procédé de préparation d'agents de contraste
US7767196B2 (en) 2005-11-21 2010-08-03 The University Of Hong Kong Optimized relaxivity and specificity hepatobiliary MRI contrast agent
NO20055702D0 (no) 2005-12-02 2005-12-02 Amersham Health As Contrast agents
US7892520B2 (en) 2006-07-31 2011-02-22 The Hong Kong University Of Science And Technology Solid-state synthesis of iron oxide nanoparticles
CN103951586B (zh) 2007-07-12 2015-05-27 通用电气医疗集团股份有限公司 造影剂
DE102008006711A1 (de) 2008-01-30 2009-08-13 Siemens Aktiengesellschaft Medizinische Diagnose- oder Therapieeinheit und Verfahren zur Verbesserung von Untersuchungs- bzw. Behandlungsabläufen mit einer medizinischen Diagnose- oder Therapieeinheit
DE102008064400A1 (de) * 2008-06-02 2009-12-03 Rohde & Schwarz Gmbh & Co. Kg Mikrowellenuntersuchung mit einem Kontrastmittel
WO2010124117A2 (fr) 2009-04-22 2010-10-28 Lifewave, Inc. Dispositif et procédés de contrôle foetal
DE102009021232B4 (de) 2009-05-14 2017-04-27 Siemens Healthcare Gmbh Patientenliege, Verfahren für eine Patientenliege und bildgebendes medizinisches Gerät
US7754920B1 (en) 2009-07-21 2010-07-13 Ge Healthcare As Solvent reduction in crystallisation of intermediate for non-ionic X-ray contrast agents
GB0920839D0 (en) * 2009-11-27 2010-01-13 Univ Bristol Contrast agents for medical imaging

Also Published As

Publication number Publication date
WO2012136813A2 (fr) 2012-10-11
WO2012136813A3 (fr) 2013-01-17

Similar Documents

Publication Publication Date Title
EP2563228B8 (fr) Couplage d'une sonde à ultrasons à la peau
WO2012149299A3 (fr) Procédés de traitement du cancer et de maladies inflammatoires au moyen de céréblon en tant que prédicteur
EP2696771B8 (fr) Caractérisation vasculaire utilisant l'imagerie ultrasonore
WO2011161226A3 (fr) Nouvelle formulation d'anticorps
PL2773331T3 (pl) Preparaty do leczenia cukrzycy
FR2972915B1 (fr) Systeme d'imagerie medicale multiplan
PL2542142T3 (pl) System do podawania leków na bazie wartości moczu
WO2013089882A3 (fr) Fusions de gènes récurrentes dans le cancer du sein
EP2667237A4 (fr) Équipement et procédé pour l'exploration, l'établissement de diagnostic ou l'aide à l'établissement de diagnostic et le traitement de problèmes fonctionnels de la vue
WO2013052647A3 (fr) Formulations et utilisations d'agonistes sélectifs du récepteur de l'acide rétinoïque
WO2012158780A3 (fr) Signature du cancer du poumon
WO2012109466A3 (fr) Arn long non codant spry4-it1 comme agent de diagnostic et thérapeutique
EP2663964A1 (fr) Système d'imagerie tomographique à deux énergies
EP2577298A4 (fr) Diagnostic du cancer
WO2012131001A3 (fr) Coussin pour interface patient
EP2990040A4 (fr) Agent thérapeutique pour maladie du fond de l'oeil
IL229607B (en) A method for diagnosing Gaucher's disease
IL230959A0 (en) A device for the treatment of eye disease
EP2666122A1 (fr) Mise en uvre optimisée de rétroprojection pour tomodensitométrie (tdm)
WO2012136813A3 (fr) Agents pour un diagnostic par radar médical
EP2547395B8 (fr) Procédé de fabrication d'une electrode a usage médical et électrode obtenue par la mise en oeuvre de ce procédé
EP2575926B8 (fr) Appareil pour le traitement du sang
EP2887068B8 (fr) Procédé pour améliorer le diagnostic d'infections invasives par Candida via la détection d'une protéine FBA1
김영석 Transabdominal Ultrasound (TAUS)
PL2456445T3 (pl) Środek do leczenia chorób skóry

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12715900

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12715900

Country of ref document: EP

Kind code of ref document: A2